Andreas Argyrides
Stock Analyst at Oppenheimer
(4.45)
# 345
Out of 4,711 analysts
98
Total ratings
52.38%
Success rate
20.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Maintains: Outperform | $102 → $63 | $17.03 | +269.94% | 6 | Dec 16, 2024 | |
| ASND Ascendis Pharma | Reiterates: Outperform | $181 | $136.38 | +32.72% | 9 | Nov 15, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $35 | $11.41 | +206.75% | 1 | Oct 16, 2024 | |
| LRMR Larimar Therapeutics | Initiates: Outperform | $26 | $4.01 | +548.38% | 1 | Oct 16, 2024 | |
| RGLS Regulus Therapeutics | Reiterates: Outperform | $7 | $1.59 | +340.25% | 1 | Aug 14, 2024 | |
| RANI Rani Therapeutics Holdings | Initiates: Outperform | $17 | $1.40 | +1,114.29% | 4 | Aug 2, 2024 | |
| LQDA Liquidia | Initiates: Perform | n/a | $11.10 | - | 6 | Jun 25, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | $104 | $52.17 | +99.35% | 14 | Jun 25, 2024 | |
| CLSD Clearside Biomedical | Initiates: Outperform | $5 | $0.87 | +473.20% | 1 | Jun 25, 2024 | |
| GOSS Gossamer Bio | Initiates: Outperform | $9 | $0.84 | +971.43% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $11.18 | +69.95% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $9 | $3.65 | +146.58% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $16.98 | +70.79% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $7.62 | +175.59% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $118.97 | +88.28% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $18.98 | +200.32% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.96 | - | 6 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $1.00 | +600.00% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $6.85 | +45.99% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $2.47 | +304.86% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $65.66 | +6.61% | 6 | Aug 1, 2023 |
Keros Therapeutics
Dec 16, 2024
Maintains: Outperform
Price Target: $102 → $63
Current: $17.03
Upside: +269.94%
Ascendis Pharma
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $136.38
Upside: +32.72%
Benitec Biopharma
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $11.41
Upside: +206.75%
Larimar Therapeutics
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $4.01
Upside: +548.38%
Regulus Therapeutics
Aug 14, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.59
Upside: +340.25%
Rani Therapeutics Holdings
Aug 2, 2024
Initiates: Outperform
Price Target: $17
Current: $1.40
Upside: +1,114.29%
Liquidia
Jun 25, 2024
Initiates: Perform
Price Target: n/a
Current: $11.10
Upside: -
MoonLake Immunotherapeutics
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $52.17
Upside: +99.35%
Clearside Biomedical
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $0.87
Upside: +473.20%
Gossamer Bio
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $0.84
Upside: +971.43%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $11.18
Upside: +69.95%
Mar 7, 2024
Maintains: Outperform
Price Target: $4 → $9
Current: $3.65
Upside: +146.58%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $16.98
Upside: +70.79%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $7.62
Upside: +175.59%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $118.97
Upside: +88.28%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $18.98
Upside: +200.32%
Nov 16, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.96
Upside: -
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $1.00
Upside: +600.00%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $6.85
Upside: +45.99%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $2.47
Upside: +304.86%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $65.66
Upside: +6.61%